Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone
Interventions: Naloxone 2 MG, Saline 2ml; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: CTP-692, Placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Healthy
Interventions: IXT-m200, Placebo; Drug · Other
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Cancer, Malignant Tumors
Interventions: E7974; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Miami, Florida • New Brunswick, New Jersey

Conditions: Safety Issues
Interventions: EQU-001, Placebo; Drug
Lead sponsor: Equilibre Biopharmaceuticals B.V.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Cystic Fibrosis
Interventions: QAU145, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza, Healthy
Interventions: Bivalent influenza vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Stockbridge, Georgia • Portland, Oregon

Conditions: Type 2 Diabetes Mellitus
Interventions: placebo, GSK376501; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Shigellosis
Interventions: 240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Pain, Post-operative
Interventions: N1539, Intravenous Placebo; Drug
Lead sponsor: Baudax Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Pasadena, Maryland

Conditions: Acne Vulgaris
Interventions: B244, Placebo; Drug
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: ST-elevation Myocardial Infarction (STEMI)
Interventions: zalunfiban, Placebo; Drug
Lead sponsor: CeleCor Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Anchorage, Alaska • Royal Oak, Michigan • St Louis, Missouri + 2 more

Conditions: Healthy Volunteer
Interventions: MT1013; Drug
Lead sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Subjects
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Amenorrhea
Interventions: Proellex; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Abnormalities, Cardiovascular
Interventions: Volanesorsen, Moxifloxacin, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Allergic Rhinitis
Interventions: Placebo, Allegra, Allegra-D, PF-03654746; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine, Placebos; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more

Conditions: Diphtheria, Pertussis, Tetanus
Interventions: Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Durham, North Carolina • Houston, Texas • Seattle, Washington

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Acute Liver Failure, Hepatic Encephalopathy
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: Up to 18 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more

Conditions: Prostatic Neoplasms
Interventions: Docetaxel, PSK®, Docetaxel, Placebo; Drug
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hereditary Hemochromatosis
Interventions: LJPC-401, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Glioblastoma
Interventions: Zimberelimab, Domvanalimab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: San Francisco, California • New Haven, Connecticut • Boston, Massachusetts

Search by objective public record fields.

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

Safety, Tolerability, and Pharmacokinetics of IXT-m200

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

D2560C00015 FluMist Annual Safety Study 2018

A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

MT1013 Clinical TRIAL In Healthy Subject

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Determination of the Lowest, Safe and Effective Dose of Proellex

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

Pertussis Vaccine in Healthy Pregnant Women

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

AB154 Combined With AB122 for Recurrent Glioblastoma